Article: Prehospital Administration Of Clot-Buster Beneficial For Heart-Attack Patients.

2001 OCT 5 - (NewsRx.com & NewsRx.net) --

A study presented September 2, 2001, at the European Society of Cardiology Congress appears to demonstrate the benefits of the clot-dissolving agent Retavase (reteplase) in the treatment of heart-attack patients.

The study, known as ER-TIMI 19, reported that doctors could accelerate the treatment of heart attack patients by 33 minutes by administering Retavase in the ambulance rather than waiting until the patient reached the hospital.

According to the U.S. National Institutes of Health (NIH), half of the 500,000 deaths from heart attacks each year occur within the first hour of experiencing symptoms ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!